Status:

COMPLETED

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Obesity

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in ...

Eligibility Criteria

Inclusion

  • Male.
  • Age 18-55 years (both inclusive) at the time of signing the informed consent.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
  • For Japanese participants, both parents of Japanese descent and both paternal and maternal grandparents of Japanese descent.
  • For Caucasian participants, self-reported European descent or white Latin-American descent.
  • BMI 18.5-24.9 kg/m\^2 (both inclusive) at screening.

Exclusion

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Previous randomisation in this study.
  • Previous rescreening for this study.
  • History of Major Depressive Disorder within the last 2 years from screening.
  • Presence or history of any psychiatric disorders (e.g., schizophrenia, bipolar disorder, eating disorders, depression, and anxiety) as judged by the investigator.
  • Suicidal ideation corresponding to type 4 or 5 or suicidal behaviour on the Columbia-Suicide Severity Rating Scale (C-SSRS) as assessed at screening or any history of suicidal attempts.
  • A Patient Health Questionnaire 9 (PHQ-9) score greater than 9 as assessed at screening.

Key Trial Info

Start Date :

August 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2024

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT06542536

Start Date

August 9 2024

End Date

October 25 2024

Last Update

November 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Altasciences Clinical LA, Inc.

Cypress, California, United States, 90630

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men | DecenTrialz